Drug Type Small molecule drug |
Synonyms Henagliflozin, SHR-3824, 瑞沁 |
Target |
Mechanism SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (31 Dec 2021), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC22H24ClFO7 |
InChIKeyHYTPDMFFHVZBOR-VNXMGFANSA-N |
CAS Registry1623804-44-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | CN | 31 Dec 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | CN | 02 Nov 2017 | |
Diabetes Mellitus | Phase 1 | CN | 28 Aug 2019 | |
Hepatic Insufficiency | Phase 1 | CN | 15 Nov 2015 | |
Liver Diseases | Phase 1 | CN | 01 Jun 2015 | |
Chronic Kidney Diseases | IND Approval | CN | 27 Nov 2023 |
Corporate Publications Manual | Phase 3 | - | otzojmfumw(cwxsizruxu) = ievnyqkhbe jqnnhiavdx (yguthybbga ) View more | Positive | 08 Jan 2024 | ||
otzojmfumw(cwxsizruxu) = ecgidkipkl jqnnhiavdx (yguthybbga ) View more | |||||||
Phase 4 | 20 | zxwvplhlhs(jdxllvoeuh) = fbourmvzfm ewmhwyikyt (rruavvijgs ) View more | Positive | 01 Nov 2023 | |||
zxwvplhlhs(jdxllvoeuh) = sxxtarqhxj ewmhwyikyt (rruavvijgs ) View more |